Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1Bezafibrate
(D01366)		1件: Bezafibrate1件: Bezafibrate (D01366) 💬 1件: NR1C1 💬 10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬8件: 20, 93, 94, 160, 296, 316, 324, 344 💬
2Bezafibrate (400MG) IN addition TO standard 15-20 MG/KG/jour udca therapy
(D01366)		2件: Bezafibrate,
Ursodeoxycholic acid		2件: Ursodiol ,
Bezafibrate (D01366) 💬 		2件: NR1C1,
NR1H4 💬 		11件: Adipocytokine signaling pathway, Alcoholic liver disease, Bile secretion, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 94 💬
3Bezafibrate 100 MG
(D01366)		1件: Bezafibrate1件: Bezafibrate (D01366) 💬 1件: NR1C1 💬 10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93 💬
4Bezafibrate 200 MG
(D01366)		1件: Bezafibrate1件: Bezafibrate (D01366) 💬 1件: NR1C1 💬 10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93 💬
5Bezafibrate 200 MG IN addition TO udca therapy
(D01366)		2件: Bezafibrate,
Ursodeoxycholic acid		2件: Ursodiol ,
Bezafibrate (D01366) 💬 		2件: NR1C1,
NR1H4 💬 		11件: Adipocytokine signaling pathway, Alcoholic liver disease, Bile secretion, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93 💬
6Bezafibrate 200 MG oral tablet
(D01366)		1件: Bezafibrate1件: Bezafibrate (D01366) 💬 1件: NR1C1 💬 10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93 💬
7Bezafibrate 400 MG
(D01366)		1件: Bezafibrate1件: Bezafibrate (D01366) 💬 1件: NR1C1 💬 10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93 💬
8Bezafibrate 400 MG IN addition TO udca therapy
(D01366)		2件: Bezafibrate,
Ursodeoxycholic acid		2件: Ursodiol ,
Bezafibrate (D01366) 💬 		2件: NR1C1,
NR1H4 💬 		11件: Adipocytokine signaling pathway, Alcoholic liver disease, Bile secretion, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93 💬
9Bezafibrate IR
(D01366)		1件: Bezafibrate1件: Bezafibrate (D01366) 💬 1件: NR1C1 💬 10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93 💬
10Bezafibrate SR
(D01366)		1件: Bezafibrate1件: Bezafibrate (D01366) 💬 1件: NR1C1 💬 10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93 💬
11Bezafibrate, beza, BZF, bezalip
(D01366)		1件: Bezafibrate1件: Bezafibrate (D01366) 💬 1件: NR1C1 💬 10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93 💬
12Bezafibrate, beza, BZF, bezalip mono
(D01366)		1件: Bezafibrate1件: Bezafibrate (D01366) 💬 1件: NR1C1 💬 10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93 💬